France · Delayed Price · Currency is EUR Innate Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Key clinical programs are advancing: IPH4502 shows strong differentiation and is targeting post-PADCEV settings, lacutamab is set for a phase III confirmatory trial with FDA alignment, and Monalizumab's pivotal lung cancer data is expected in the second half of 2024. Funding options are actively being pursued.
Fiscal Year 2025
-
Advanced three core oncology assets with strong clinical progress and regulatory milestones. Revenue reached EUR 9 million, R&D expenses fell 16% year-over-year, and cash runway extends through Q3 2026. Key late-stage trials and commercial strategies are on track.
-
Three lead assets—lacutamab, monalizumab, and IPH4502—are advancing, with lacutamab on an accelerated FDA approval path and monalizumab's phase III readout expected in 2026. IPH4502 shows promise in resistant tumors, and significant commercial milestones are anticipated.
-
Lacutamab advanced with FDA clearance for phase III in CTCL, targeting accelerated approval in Sézary syndrome. IPH4502 and Monalizumab also progressing, with strong financial runway and expanded commercial potential based on new real-world data.
-
Lacutamab is advancing toward accelerated approval in Sézary syndrome, supported by strong Phase II data, a favorable safety profile, and expanded commercial opportunity based on new claims data. Phase III initiation is planned for early 2026, with significant revenue potential projected across CTCL segments.
-
Strategic focus is now on IPH4502, Lacutamab, and Monalizumab, with strong clinical progress and a streamlined organization. Financials show $4.9M in H1 2025 revenue and $70.4M cash, funding operations through Q3 2026. Key milestones for all lead assets are on track.
-
The company is advancing a differentiated antibody pipeline, highlighted by the ANKET platform and ADCs, with key assets in late-stage trials and promising regulatory progress. Sanofi's investment and strategic shifts validate the platform, while multiple data readouts and partnership milestones are expected by early 2025.
-
Strategic focus is on advancing NK cell engagers, ADCs, and late-stage assets, supported by a strong cash position and a recent EUR 50 million Sanofi investment. Key programs are progressing in the clinic, with lacutamab seeking a partner for phase III funding.
-
The event detailed a robust pipeline with three strategic pillars: ANKET platform, ADCs, and late-stage assets. Key assets are advancing rapidly, with pivotal data and regulatory milestones expected in 2024–2026. Financial runway extends to mid-2026.
-
Leadership outlined a sharpened focus on differentiated ADC and ANKET platforms, with rapid clinical progress and strategic partnering for key assets. Regulatory and clinical milestones are anticipated for lacutamab and Monalizumab, while the ANKET platform advances in hematologic and autoimmune indications.
-
IPH4502, a novel Nectin-4 ADC with an exatecan payload, shows superior preclinical efficacy and safety, especially in low-expressing and resistant tumors. The first-in-human trial is underway, targeting both Padcev-resistant and other Nectin-4 positive cancers, with initial data expected by end of 2025.
-
A new CEO with deep oncology experience is steering a strategy focused on advancing a robust pipeline of NK cell engagers, ADCs, and late-stage assets. Key milestones include FDA-aligned accelerated approval for lacutamab, promising clinical data, and strong partnerships with Sanofi and AstraZeneca.
Fiscal Year 2024
-
Advanced clinical programs in oncology and autoimmune diseases, highlighted by FDA breakthrough therapy designation for lacutamab and strong progress in IPH6501 and IPH4502. 2024 revenue reached €20.1M, with cash runway through mid-2026 and key data readouts expected by year-end.
-
Pipeline advances include FDA support for lacutamab's accelerated approval in Sézary syndrome, phase I start for IPH4502, and continued ANKET progress. Cash reserves of €96.4M fund operations through 2025, with partnership discussions ongoing for key assets.
-
Recent advances highlight the promise of NK cell engagers, CAR-NK therapies, and costimulatory bispecifics in overcoming resistance and improving safety in cancer immunotherapy. Myeloid cell reprogramming and antigen presentation defects are key resistance mechanisms, with new strategies targeting these pathways showing early clinical success.
-
H1 2024 saw strong pipeline progress, with lacutamab advancing in CTCL, ANKET and ADC assets moving through clinical stages, and partnerships with AstraZeneca and Sanofi yielding key milestones. Revenue reached €12.3M, with a cash runway through 2025.
-
Phase II TELLOMAK data show lacutamab achieved a 16.8% global response rate and 10.2-month median PFS in heavily pretreated mycosis fungoides, with a favorable safety profile and activity across KIR3DL2 expression levels, supporting further development and potential expansion of eligible patients.